La insuficiencia cardiaca (IC) con función sistólica conservada se caracteriza por una alteración en el llenado ventricular que acontece durante la diástole debido a un defecto de elasticidad y/o distensibilidad. Más de una tercera parte de todas las IC lo son por disfunción diastólica, cuyo sustrato anatómico es, en una importante proporción de casos, la hipertrofia ventricular izquierda, estrechamente relacionada con la hipertensión arterial crónica. El tratamiento con fármacos que bloquean el sistema renina-angiotensina-aldosterona, además de controlar la presión arterial, ha demostrado mejorar la capacidad funcional de estos pacientes. Además, existen evidencias de que estos compuestos son eficaces para reducir tanto la masa ventricular como la fibrosis miocárdica. Los resultados del estudio CHARM Preservado indican que el tratamiento con candesartán es de utilidad clínica para el tratamiento de estos pacientes al limitar el riesgo de hospitalizaciones y debe tenerse en cuenta al plantear la estrategia terapéutica de este patrón fisiopatológico de la IC.
Palabras clave
Insuficiencia cardiaca
Función sistólica normal
Candesartán
Este artículo solo puede leerse en
pdf
Bibliografía
[1.]
R.C. Davis, F.D.R. Hobbs, G.Y.H. Lip.
ABC of Heart Failure. History and epidemiology.
BMJ, (2000), 320 pp. 39-42
[2.]
W.J. Remme, J.J. McMurray, B. Rauch, F. Zannard, K. Keukelaar, A. Cohen-Solal, et al.
Public awareness of heart failure in Europe: first results from SHAPE.
Eur Heart J, (2005), 26 pp. 2413-2421
[3.]
K. Hogg, K. Swedberg, J.J. McMurray.
Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis.
J Am Coll Cardiol, (2004), 43 pp. 317-327
[4.]
A. Varela, L. Grigorian, E. Barge, P. Bassante, M. Gil, J.R. González-Juanatey.
Heart failure in patients with preserved and deteriorated left ventricular ejection fraction.
Heart, (2005), 91 pp. 489-494
[5.]
A. González, B. López, J. Diez.
New directions in the assessment and treatment of hypertensive heart disease.
Curr Opin Nephrol Hypertens, (2005), 14 pp. 428-434
[6.]
L. Grigorian, A. Varela, A. Virgos, P. Rigueiro, J.M. García, J.R. González-Juanatey.
Evolución a largo plazo de la prescripción de fármacos en pacientes hospitalizados por insuficiencia cardiaca congestiva. Influencia del patrón de disfunción.
Rev Esp Cardiol, (2005), 58 pp. 381-388
[7.]
L. Grigorian, J.R. González-Juanatey, A. Varela, J.M. García, A. Virgos.
The death rate among hospitalized heart failure patients with normal and depressed left ventricular ejection fraction in the year following discharge: evolution over a 10-year period.
Eur Heart J, (2005), 26 pp. 2251-2258
[8.]
K. Swedberg, J. Cleland, H. Dargie, H. Drexler, F. Follath, M. Komajda, et al.
Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary [update 2005].
Eur Heart J, (2005), 26 pp. 1115-1140
[9.]
J.K. Ghali, S. Kadakia, A. Bhatt, R. Cooper, Y. Liao.
Survival of heart failure patients with preserved versus impaired systolic function: the prognostic implication of blood pressure.
Am Heart J, (1992), 123 pp. 993-997
[10.]
A. Varela, J.R. González-Juanatey, P. Basante, R. Trillo, J. García-Seara, J.L. Martínez-Sande, et al.
Clinical characteristics and prognosis of hospitalised in patients with heart failure and preserved or reduced left ventricular ejection fraction.
Heart, (2002), 88 pp. 249-254
[11.]
S. Yusuf, M.A. Pfeffer, K. Swedberg, C.B. Granger, P. Held, J.J.V. McMurray, For the CHARM Investigators and Committees, et al.
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.
Lancet, (2003), 362 pp. 777-781
[12.]
J.G. Warner Jr, D.C. Metzger, D.W. Kitzman, D.J. Wesley, W.C. Little.
Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise.
J Am Coll Cardiol, (1999), 33 pp. 1567-1572
[13.]
S. Kasama, T. Toyama, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suziki, et al.
Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular left ventricular ejection fraction.
J Am Coll Cardiol, (2005), 45 pp. 661-667
[14.]
M.A. Pfeffer, K. Swedberg, C.B. Granger, P. Held, J.J. McMurray, E.L. Michelson, For the CHARM Investigators and Committees, et al.
Effects of candesartan on mortality and morbidity in patients with chronic heart failure. The CHARM-Overall programme.
Lancet, (2003), 362 pp. 759-766
[15.]
J.J. McMurray, J. Ostergren, K. Swedberg, C.B. Granger, P. Held, E.L. Michelson, For the CHARM Investigators and Committees, et al.
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
Lancet, (2003), 362 pp. 767-771
[16.]
C.B. Granger, J.J. McMurray, S. Yusuf, P. Held, E.L. Michelson, B. Olofsson, For the CHARM Investigators and Committees, et al.
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
Lancet, (2003), 362 pp. 772-776
[17.]
K. Swedberg, M. Pfeffer, A. Cohen-Solal, A. Ducharme, C. Granger, E. Michelson, et al.
Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan: results from the CHARM study (abst.).
J Am Coll Cardiol, (2004), 43 pp. 222A
[18.]
A. Varela, L. Grigorian, E. Barge, P. Mazon, P. Rigueiro, J.R. González-Juanatey.
Influence of diabetes on the survival of patients hospitalized with heart failure: A 12-year study.
Eur J Heart Fail, (2005), 7 pp. 859-864
[19.]
E. O’Meara, S. Salomon, J. McMurray, M. Pfeffer, S. Yusuf, E. Michelson, et al.
Effect of candesartan on New York Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
Eur Heart J, (2004), 25 pp. 1920-1926
[20.]
S.D. Solomon, D. Wang, P. Finn, H. Skali, L. Zornoff, J.J. McMurray, et al.
Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
Circulation, (2005), 110 pp. 2180-2183
Copyright ©
2006. Sociedad Española de Cardiología